Zobrazeno 1 - 10
of 325
pro vyhledávání: '"C. Kent Osborne"'
Publikováno v:
Journal of Clinical Oncology. 41:1331-1338
PURPOSE Immunohistochemistry (IHC) is a newer technique for assessing the estrogen receptor (ER) status of breast cancers, with the potential to overcome many of the shortcomings associated with the traditional ligand-binding assay (LBA). The purpose
Autor:
Jonathan T. Lei, Chen Huang, Ramakrishnan R. Srinivasan, Suhas Vasaikar, Lacey E. Dobrolecki, Alaina N. Lewis, Na Zhao, Jin Cao, Susan G. Hilsenbeck, C. Kent Osborne, Mothaffar Rimawi, Matthew J. Ellis, Varduhi Petrosyan, Alexander B. Saltzman, Anna Malovannaya, John D. Landua, Bo Wen, Antrix Jain, Gerburg M. Wulf, Shunqiang Li, Daniel C. Kraushaar, Tao Wang, Xi Chen, Gloria V. Echeverria, Meenakshi Anurag, Bing Zhang, Michael T. Lewis
Publikováno v:
Cancer Research. 83:P2-23
Background: Triple-negative breast cancer (TNBC) patients frequently receive combination chemotherapy treatment, but a direct comparison of response to carboplatin, docetaxel, and their combination in 50 TNBC patient-derived xenografts (PDXs) showed
Autor:
Snehal Patel, Jaye Thompson, Mira Patel, F. Joseph Daugherty, C. Kent Osborne, Mothaffar Rimawi
Publikováno v:
Cancer Research. 83:OT2-10
Background: GP2 is a biologic nine amino acid peptide of the HER2/neu protein delivered in combination with Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) that stimulates an immune response targeting HER2/neu expressing cancers, the combin
Autor:
Katherine L. Pogue-Geile, Sai K. Maley, Rim S. Kim, Ying Wang, Roberto Salgado, Corey Lipchik, Huichen Feng, Reena S. Cecchini, Samuel A. Jacobs, Ashok Srinivasan, Eleftherios (Terry) Mamounas, Charles E. Geyer Jr, Priya Rastogi, C. Kent Osborne, Soonmyung Paik, Norman Wolmark, Peter C. Lucas, Mothaffar Rimawi
Publikováno v:
Cancer Research. 83:P1-04
Background: The primary aim of the NRG Oncology/NSABP B-52 clinical trial was to test if estrogen deprivation (ED) administered concomitantly with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP), would improve the pCR rate in p
Autor:
Fu-Tien Liao, Tia Gordon, Chia Chia Liu, Pier Selenica, Yingjie Zhu, Juber Patel, Sarmistha Nanda, Lanfang Qin, Xiaoyong Fu, Andrea Gazzo, Antonio Marra, Juan Blanco-Heredia, Britta Weigelt, Jorge Reis-Filho, C. Kent Osborne, Mothaffar Rimawi, Rachel Schiff, Jamunarani Veeraraghavan
Publikováno v:
Cancer Research. 83:P1-13
Background: The HER2-specific tyrosine kinase inhibitor (TKI) tucatinib (Tuca) recently approved for advanced HER2+ breast cancer is making a move towards the early setting. Given its growing use, resistance is inevitable, as observed in the HER2CLIM
Autor:
Jamunarani Veeraraghavan, Carolina Gutierrez, Carmine De Angelis, Robert Davis, Tao Wang, Tomas Pascual, Pier Selenica, Katherine Sanchez, Hiroaki Nitta, Monesh Kapadia, Anne C. Pavlick, Patricia Galván, Brent Rexer, Andres Forero-Torres, Rita Nanda, Anna M. Storniolo, Ian E. Krop, Matthew P. Goetz, Julie R. Nangia, Antonio C. Wolff, Britta Weigelt, Jorge S. Reis-Filho, Susan G. Hilsenbeck, Aleix Prat, C. Kent Osborne, Rachel Schiff, Mothaffar F. Rimawi
Publikováno v:
Clinical Cancer Research.
Background: Clinical trials reported 25-30% pathologic complete response (pCR) rates in HER2+ breast cancer (BC) patients treated with anti-HER2 therapies without chemotherapy. We hypothesize that a multiparameter classifier can identify patients wit
Autor:
Meenakshi Anurag, Eric J. Jaehnig, Karsten Krug, Jonathan T. Lei, Erik J. Bergstrom, Beom-Jun Kim, Tanmayi D. Vashist, Anh Minh Tran Huynh, Yongchao Dou, Xuxu Gou, Chen Huang, Zhiao Shi, Bo Wen, Viktoriya Korchina, Richard A. Gibbs, Donna M. Muzny, Harshavardhan Doddapaneni, Lacey E. Dobrolecki, Henry Rodriguez, Ana I. Robles, Tara Hiltke, Michael T. Lewis, Julie R. Nangia, Maryam Nemati Shafaee, Shunqiang Li, Ian S. Hagemann, Jeremy Hoog, Bora Lim, C. Kent Osborne, D.R. Mani, Michael A. Gillette, Bing Zhang, Gloria V. Echeverria, George Miles, Mothaffar F. Rimawi, Steven A. Carr, Foluso O. Ademuyiwa, Shankha Satpathy, Matthew J. Ellis
Publikováno v:
Cancer Discovery. 12:2586-2605
Microscaled proteogenomics was deployed to probe the molecular basis for differential response to neoadjuvant carboplatin and docetaxel combination chemotherapy for triple-negative breast cancer (TNBC). Proteomic analyses of pretreatment patient biop
Autor:
Mothaffar F. Rimawi, Raf Poppe, Christine Wohlfarth, Valentine Revelant, Dirk Klingbiel, C. Kent Osborne, Sabino De Placido, Jean-Marc Ferrero, Juan de la Haba Rodríguez, Grazia Arpino
Investigator list and Supplementary Table 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f7a7da8da56b23d9af0a541f6194ad9
https://doi.org/10.1158/1078-0432.22633063.v1
https://doi.org/10.1158/1078-0432.22633063.v1
Autor:
Mothaffar F. Rimawi, Raf Poppe, Christine Wohlfarth, Valentine Revelant, Dirk Klingbiel, C. Kent Osborne, Sabino De Placido, Jean-Marc Ferrero, Juan de la Haba Rodríguez, Grazia Arpino
Purpose:In PERTAIN's primary analysis (31 months’ median follow-up), adding pertuzumab to trastuzumab and an aromatase inhibitor (AI) with/without chemotherapy significantly improved progression-free survival (PFS) in patients with previously untre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38c31f393b926d6f08d7c60c2f0042e0
https://doi.org/10.1158/1078-0432.c.6533152
https://doi.org/10.1158/1078-0432.c.6533152
Autor:
Matthew J. Ellis, Shankha Satpathy, Foluso O. Ademuyiwa, Steven A. Carr, Mothaffar F. Rimawi, George Miles, Gloria V. Echeverria, Bing Zhang, Michael A. Gillette, D.R. Mani, C. Kent Osborne, Bora Lim, Jeremy Hoog, Ian S. Hagemann, Shunqiang Li, Maryam Nemati Shafaee, Julie R. Nangia, Michael T. Lewis, Tara Hiltke, Ana I. Robles, Henry Rodriguez, Lacey E. Dobrolecki, Harshavardhan Doddapaneni, Donna M. Muzny, Richard A. Gibbs, Viktoriya Korchina, Bo Wen, Zhiao Shi, Chen Huang, Xuxu Gou, Yongchao Dou, Anh Minh Tran Huynh, Tanmayi D. Vashist, Beom-Jun Kim, Erik J. Bergstrom, Jonathan T. Lei, Karsten Krug, Eric J. Jaehnig, Meenakshi Anurag
Microscaled proteogenomics was deployed to probe the molecular basis for differential response to neoadjuvant carboplatin and docetaxel combination chemotherapy for triple-negative breast cancer (TNBC). Proteomic analyses of pretreatment patient biop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2213f3db6710d869c1c4f3f803aa9523
https://doi.org/10.1158/2159-8290.c.6549759.v1
https://doi.org/10.1158/2159-8290.c.6549759.v1